ReviewClinical reviews in allergy & immunology2007
Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus?
Review in Clinical reviews in allergy & immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Serological and clinical associations of autoantibodies in Chinese patients with new-onset systemic lupus erythematosus.Scientific reports · 2023Article
- Study on the correlation between anti-ribosomal P protein antibody and systemic lupus erythematosus.Medicine · 2020Observational
- Autoantibodies in SLE: Specificities, Isotypes and Receptors.Antibodies (Basel, Switzerland) · 2016Review
- Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus.PloS one · 2015Article
- Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.Journal of clinical laboratory analysis · 2013Article
- Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus.Arthritis research & therapy · 2011Article
- How common are extraribosomal functions of ribosomal proteins?Molecular cell · 2009Review
- Vasculitis: current status and future directions.Clinical reviews in allergy & immunology · 2008Article
- Systemic lupus erythematosus involving the nervous system: presentation, pathogenesis, and management.Clinical reviews in allergy & immunology · 2008Review
- Cutting edge issues in autoimmunity.Clinical reviews in allergy & immunology · 2008Article
- Mapping the genetic architecture of gene expression in human liver.PLoS biology · 2008Article
- Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies.Arthritis research & therapy · 2008Article
- The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot.Journal of molecular medicine (Berlin, Germany) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a prototypal auto-immune disorder characterized with multiple organ involvement resulting in disability and increased mortality. Immune regulatory disturbances cumulate in activation of B cells and consequent auto-antibody production. Antigens for these auto-antibodies can be nuclear components and cytoplasmic elements. Anti-P antibodies react against acidic phosphorylated ribosomal proteins P0, P1, and P2 (with molecular mass of 38, 19, and 17 kDa, respectively) and are located on the S60 subunit of ribosomes. Ribosomal P proteins share a common 22-amino acid sequence that is present in the carboxyl-terminal. Anti-P antibodies can be detected in approx 15 to 20% of patients with lupus by several immunoassays, most frequently by enzyme-linked immunosorbent assay (ELISA) and/or Western blotting. However, no standardized assay is available. Auto-antibodies against eukaryotic P proteins appear highly specific for SLE; therefore, they can be used as diagnostic marker for the disease. Furthermore, association has been described with particular manifestations of lupus, especially with neuropsychiatric, renal, and hepatic involvements. Anti-P positivity and the titer of anti-P antibodies also fluctuate with clinical disease activity. Despite several lines of evidence, results are conflicting regarding the existence of such associations. Discrepancies can be explained by different study set-up or study population; it also can be attributed to the different sensitivity of tests used for the detection of anti-P antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.